Episode 14: Paul Le Floch talks BCI, Coma and Start Up Dynamics

5 Oct

How can softer materials make implantable brain-computer interfaces safer, more stable and clinically useful? In this episode of The Business of Neurotech, Adam Fraser is joined by Dr Paul Le Floch, co-founder and CEO of Axoft, to explore how his materials science background led to Fleuron, a soft neural interface platform designed to reach deep brain regions while maintaining high-density recordings. Dr Le Floch explains why Axoft is initially focusing on disorders of consciousness, how the company is taking a stepwise path through FDA clearance and what its early clinical work revealed about turning novel biomaterials into medical devices. He also discusses the realities of raising a $55 million Series A, competing in a fast-moving BCI market, financing research through materials sales and learning to pitch a long-term vision as a scientist-founder. Tune in to learn what it takes to build an invasive BCI company focused on better materials, unmet clinical needs and patient impact.

Key Points From This Episode:

[01:29] Dr Le Floch’s path from materials science at Harvard to founding Axoft.
[03:21] Discover why the brain’s electrical complexity drew him into neuroscience.
[04:57] Unpack how Fleuron’s softness aims to improve compatibility with brain tissue.
[06:44] Explore why stable neural data links efficacy with reduced tissue disruption.
[08:58] Compare invasiveness with signal quality and where Axoft sits on that continuum.
[12:19] Find out why disorders of consciousness became Axoft’s first clinical focus.
[16:26] Follow the roadmap from diagnosis and prognosis towards decoding communication.
[18:12] Understand Axoft’s stepwise regulatory strategy for a temporary inpatient device.
[20:15] He shares his experience working with the FDA in an emerging BCI category.
[21:34] Uncover the clinical evidence and commercial plan behind Axoft’s Series A.
[23:25] The clearance, manufacturing and clinical milestones needed for Series B funding.
[25:14] Gain insight into why BCI’s difficult venture capital environment is still worth the risk.
[28:47] Unpack Axoft’s strategy in a field of well-funded but complementary competitors.
[30:12] Hear how materials sales fund research while providing partnership opportunities.
[33:35] Why targeted stimulation that bridges devices and drugs is capturing his attention.
[35:11] Learn how scientist-founders can move from research to vision-led application.
[37:18] Final takeaways and how to learn more about Axoft and Dr Le Floch’s work.